”We welcome the opportunity of avoiding all future payments obligations to CapNova by making the payment of this amount,” says Jeppe Øvlesen, CEO, SynAct.
For further information about the agreement between CapNova and SynAct please refer to the company’s prospectus for the listing on Aktietorget, which was published in May 2016.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Henrik Stage
CFO, SynAct Pharma AB
Telephone: +45 40 26 09 00
E-mail: [email protected]
This is information that SynAct Pharma AB is obliged to disclose under the EU’s market abuse regulation. The information was submitted by the above contact person for publication on 28 October 2016.
SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.